Heterogeneous alteration of the ERBB3–MYC axis associated with MEK inhibitor resistance in a KRAS-mutated low-grade serous ovarian cancer patient

Low-grade serous ovarian cancer (LGSOC) is relatively chemoresistant, and no precision therapy is approved for this indication. Despite promising results in phase II trials, MEK inhibitors have failed to show improved progression-free survival in a phase III trial when compared to physician's c...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cold Spring Harb Mol Case Stud
Autors principals: Colombo, Ilaria, Garg, Swati, Danesh, Arnavaz, Bruce, Jeffrey, Shaw, Patricia, Tan, Qian, Quevedo, Rene, Braunstein, Marsela, Oza, Amit M., Pugh, Trevor, Lheureux, Stephanie
Format: Artigo
Idioma:Inglês
Publicat: Cold Spring Harbor Laboratory Press 2019
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6913142/
https://ncbi.nlm.nih.gov/pubmed/31836588
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1101/mcs.a004341
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars